^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IgG-RFB4-SMPT-dgA

    Associations
    News
    Trials
    Company:
    National Cancer Institute
    Drug class:
    CD22 inhibitor
    Related drugs:
    Associations
    News
    Trials